Physician profile
Inna Bardoff
NPI 1801295803
$11,423.35
in general payments reported to CMS, 2019-2025
39 companies · $2,327 in 2025
The $2,327 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,259 · 2022: $2,493 · 2023: $2,442 · 2024: $1,902 · 2025: $2,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,570 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,569.63 |
| Education | $101.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,085.44 | 2021-2025 | |
| Janssen Biotech, INC. | $1,034.83 | 2021-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $908.72 | 2021-2025 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $675.27 | 2021-2025 | Entyvio, Gattex |
| Gilead Sciences, INC. | $523.07 | 2021-2024 | |
| Pfizer INC. | $420.00 | 2021-2025 | |
| Genzyme Corporation | $381.33 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $377.80 | 2021-2024 | Linzess |
| Celgene Corporation | $345.05 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $330.46 | 2024-2025 | Rezdiffra, Resmetirom |
| Amgen INC. | $272.39 | 2021-2023 | Amjevita, Avsola |
| Merck Sharp & Dohme LLC | $206.21 | 2021-2024 | Dificid, Zinplava |
| Ardelyx, INC. | $183.08 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $134.28 | 2023-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $129.27 | 2023 | Zeposia |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $122.57 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $116.05 | 2021-2024 | Ocaliva |
| Braintree Laboratories, INC. | $112.76 | 2021-2024 | Sutab, Suflave |
| Fresenius Kabi USA, LLC | $100.16 | 2023-2024 | Idacio |
| Phathom Pharmaceuticals, INC. | $98.38 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $91.93 | 2024-2025 | Zenpep, Vowst |
| Qol Medical, LLC | $78.74 | 2022-2023 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $77.16 | 2024-2025 | Iqirvo, Bylvay |
| Lilly USA, LLC | $75.15 | 2024-2025 | Omvoh |
| Organon LLC | $69.43 | 2021-2023 | Renflexis, Hadlima |
| Alnylam Pharmaceuticals INC. | $59.15 | 2022-2025 | Givlaari |
| Redhill Biopharma INC. | $56.56 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $53.09 | 2021-2022 | |
| Daiichi Sankyo INC. | $49.88 | 2021-2024 | Injectafer |
| Celltrion USA INC. | $45.19 | 2024-2025 | Vegzelma, Zymfentra |
| Evoke Pharma, INC. | $43.40 | 2021-2025 | |
| Pharmacosmos Therapeutics INC. | $37.26 | 2021 | |
| Mallinckrodt Hospital Products INC. | $27.59 | 2024 | Terlivaz |
| Medtronic, INC. | $21.47 | 2021 | |
| Novo Nordisk INC | $20.76 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.30 | 2023 | Cyltezo |
| Exact Sciences Corporation | $17.37 | 2023 | Cologuard Collection Kit |
| Boston Scientific Corporation | $14.56 | 2023 | Wavewriter Alpha Prime 16 |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inna Bardoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.